Weill Cornell

The medical school is launching the program with the support of a $5 million gift from investment firm WorldQuant and its founder.

Groups from Austria, Spain, Germany, and the US demonstrated that the GeneReader can reliably detect cancer mutations in tissue and liquid biopsy samples.